Highest development stage: Phase 3 (NCT04505683)

Development status: Active (as of 2022)

Gram-negative activity

Mechanism of Action/Target pathogen: Binds to bacterial penicillin-binding proteins (PBP) and interferes with bacterial cell wall integrity and synthesis. Carbapenems bind to all PBPs, with PBP2 and PBP4 as the highest-affinity targets

Additional information: Semisynthetic, derived from thienamycin, similar to ertapenem; clinical development only for China